The existence of gender difference in IL-1Ra gene polymorphism

Journal of Interferon and Cytokine Research

Volumn 27, Issue 11, 2007, Pages 931-935

  Bessler, Hanna ^a,d   Osovsky, Micky ^b,c   Beilin, Benzion ^a   Alcalay, Yifat ^a   Sirota, Lea ^b,c  

^a HASHARON HOSPITAL   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TANDEM REPEAT;

ALLELES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; POLYMORPHISM, GENETIC; SEX CHARACTERISTICS;

EID: 36849023860     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0029     Document Type: Article

References (45)

1. Bidwell JL, Keen LJ, Gallagher G, Kimberly R Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1999;1:3-19.
2. Daun JM, Ball RW, Cannon JG. Glucocorticoid sensitivity to interleukin-1 agonist and antagonist secretion: the effects of age and gender. Am. J. Physiol. 2000;278:R855-862.
3. Lynch EA, Dinarello CA, Cannon JG. Gender differences in IL-1α, Il-1β and IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion. J. Immunol. 1994;153:300-306.
4. Cullup H, Middleton PG, Duggan G, Conn JS, Dickinson AM. Environmental factors and not genotype influence the plasma level of interleukin-1 receptor antagonist in normal individuals. Clin. Exp. Immunol. 2004;137:351-358.
5. Riancho JA, Zarrabeitia MT, Amado JA, Olmos JM, Gonzalez-Macias J. Age-related difference in cytokine secretion. Gerontology 1994;40:8-12.
6. Petrovsky N, McNair P, Harrison LC. Diurnal rhythms of proinflammatory cytokine: regulation of by plasma cortisol and therapeutic implications. Cytokine 1998;10:307-312.
7. Vamvakopoulos J, Green C, Metcalfe S. Genetic control of IL-1β bioactivity through differential regulation of IL-1 receptor antagonist. Eur. J. Immunol. 2002;32:2988-2996.
8. Bailly S, Israel N, Fay M, Gourerot-Pocidalo MA, Duff GW. An intronic polymorphic repeat sequence modulates interleukin-1 alpha gene regulation. Mol. Immunol. 1996;33:999-1006.
9. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin. Infect. Dis. 2002;34:204-209.
10. Kanai T, Fukuda-Miki M, Shimoya K, Azuma C, Hashimoto K, Nobugana T, Tokugawa Y, Tsujimoto M, Saji F, Murata Y. Increased interleukin-1 and interleukin-1 receptor antagonist levels in cervical mucus in the ovulatory phase in comparison with the follicular phase. Gynecol. Obstet. Invest. 1997;43:166-170.
11. von Aulock S, Beininger S, Draing C, Guienzuis K, Dehus O, Hermann C. Gender difference in cytokine secreton on immune stimulation with LPS and LTA. J. Interferon Cytokine Res. 2006;26:887-892.
12. Bry K, Laapalainen U, Waffarn F, Teramo K, Hallman M. Influence of fetal gender on the concentration of interleukin-1 receptor antagonist in amniotic fluid and in newborn urine. Pediatr. Res. 1994;35:130-134.
13. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest. 1992;22:396-402.
14. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand. J. Immunol. 1998;47:195-198.
15. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable number of an 86-bp tandem repeat. Hum. Genet. 1993;91:403-404.
16. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 1998;16:27-55.
17. Genc MR, Gerber S, Nesin M, Witkin SS. Polymorphism in the interleukin-1 gene complex and spontaneous preterm delivery. Am. J. Obstet. Gynecol. 2002;187:157-163.
18. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin. Exp. Immunol. 1995;99:303-310.
19. Bioque G, Crusius JB, Koutroubakis I, Bouma G, Kostense PJ, Meuwissen SG, Pena AS. Allelic polymorphism in IL-1β and IL-1 receptor antagonist genes in inflammatory bowel disease. Clin. Exp. Immunol. 1995;102:379-383.
20. Wilkinson RJ, Patel P, Lleweln M, Hirsch CS, Pasvol G, Snounou G, Davidson RN, Toosi RJ. Influence of polymorphism in the genes for interleukin-1 receptor antagonist and IL-1β on tuberculosis. J. Exp. Med. 1999;189:1863-1873.
21. Rider LG, Artlett CM, Foster CB, Ahmed A, Neeman T, Chanock SJ, Jimenez SA, Miller FW. Polymorphism in IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin. Exp. Immunol. 2000;121:47-52.
22. Mwantembe O, Gaillard MC, Barkhuizen M, Pillay V, Berry SD, Dewar JB, Song E. Ethnic differences in allelic associations of the interleukin-1 gene cluster in South African patients with inflammatory bowel disease and in control individuals. Immunogenetics 2001;52:249-254.
23. Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol. Rev. 2002;82;981-1011.
24. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988;334:698-700.
25. Watkins LR, Maier SF. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu. Rev. Psychol. 2000;51:29-57.
26. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br. J. Pharmacol. 1995;115:1265-1275.
27. Cui JG, Holmin S, Mathiesen T, Meyerson BA, Linderoth B. Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy. Pain 2000;88:239-248.
28. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-475.
29. Logan DE, Rose JB. Gender difference in post-operative pain and patient controlled analgesia use among adolescent surgical patients. Pain 2004;109:481-487.
30. Taenzer AH, Clark C, Curry CS. Gender effects report of pain function after arthroscopic anterior cruciate ligament reconstruction. Anesthesiology 2000;93:670-675.
31. Miaskowski C, Gear RW, Levine JD. In: Fillingim RB, ed. Progress in Pain Research and Management, vol. 17. Seattle: IASP Press; 2000:209-230.
32. Uchiyama K, Kawai M, Tani M, Ueno M, Hama T, Yamaue H. Gender differences in postoperative pain after laparoscopic cholecystectomy. Surg. Endosc. 2006;20:448-451.
33. Fillingim RB, Gear RW. Sex differences in opioid analgesia: clinical and experimental findings. Eur. J. Pain 2004;8:314-325.
34. Riley JL, Robinson ME, Wise EA, Myers CD, Fillingim RB. Sex differences in the perception of noxious experimental stimuli: a meta-analysis. Pain 1998;74:181-187.
35. Gravell MG, Witkin SS, Haluska GJ, Edwards JL, Cook MJ, Novy MJ. An experimental model for intraamniotic infection and preterm labor in rhesus monkeys. Am. J. Obstet. Gynecol. 1994;171:1660-1667.
36. Murtha AP, Nieves A, Hauser E, Swamy GK, Yonish BA, Sinclair TR, Heine RP. Association of maternal IL-1 receptor antagonist intron 2 gene polymorphism and preterm birth. Am. J. Obstet. Gynecol. 2006; 195:1249-1253.
37. Bessler H, Osovsky M, Sirota L. Association between IL-1ra gene polymorphism and preterm delivery. Biol. Neonate 2004;85:179-183.
38. Witkin SS, Gravett MG, Haluska GJ, Novy MJ. Induction of interleukin-1 receptor antagonist in rhesus monkeys after intraamniotic infection with group B streptococci or interleukin-1 infusion. Am. J. Obstet. Gynecol. 1994;171:1668-1672.
39. Romero R, Tartakovsky B. The natural interleukin-1 receptor antagonist prevents interleukin-1 induced preterm delivery in mice. Am. J. Obstet. Gynecol. 1992;167:1041-1045.
40. Romero R, Sepulveda W, Maazor M., Brandt F, Cotton DB, Dinarello CA, Mitchell MD. The natural interleukin-1 receptor antagonist in term and preterm parturition. Am. J. Obstet. Gynecol. 1992;167:863-872.
41. Perni SC, Vardhana S, Tuttle SL, Kalish RB, Chasen ST, Witkin SS. Fetal interleukin-1 receptor antagonist gene polymorphism, intra-amniotic interleukin-1β levels, and history of spontaneous abortion. Am. J. Obstet. Gynecol. 2004;191:1318-1323.
42. Nacye RI, Burt LS, Wright DL, Blanc WA, Tatter D. Neonatal morbidity, the male disadvantage. Pediatrics 1971;48:902-906.
43. Brothwood M, Wolke D, Gamsu H, Benson J, Cooper D. Prognosis of the very low birthweight baby in relation to gender. Arch. Dis. Child. 1986;61:559-564.
44. Stevenson KD, Verter J, Fanaroff AA, Oh W, Ehrenkranz RA, Shankaran S, Donovan EF, Wright LL, Lemons JA, Tyson JE, Bouer CR, Lapile LA. Sex differences in outcomes of very low-birth infants: the newborn male disadvantage. Arch. Dis. Child. Neonatal Ed. 2000;83:F182-F185.
45. Elsmen E, Ley D, Cilio CM, Hansen-Pupp I, Hellstrom-Westas L. Umbilical cord levels of interleukin-1 receptor antagonist and neonatal outcome. Biol. Neonate 2006;89:220-226.